Oncotarget

Research Papers:

The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Guangzhi Ma _, Jing Zhang, Liyuan Yin, Hai Jiang, Weiwei Zhang, Yanlin Song and Ming Liu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:50941-50948. https://doi.org/10.18632/oncotarget.16222

Metrics: PDF 740 views  |   HTML 892 views  |   ?  


Abstract

Guangzhi Ma1,2,*, Jing Zhang3,*, Liyuan Yin1,*, Hai Jiang4, Weiwei Zhang5, Yanlin Song1 and Ming Liu1

1Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

2Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

3Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

4Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

5Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Ming Liu, email: mingliu721@aliyun.com

Keywords: pretreatment T790M, NSCLC, EGFR TKI, prognosis, meta-analysis

Received: November 17, 2016    Accepted: February 20, 2017    Published: March 15, 2017

ABSTRACT

Purpose: The outcome of pretreatment epidermal growth factor receptor (EGFR) T790M mutation in EGFR mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) is controversial, this study aimed to evaluate the prognostic role of pretreatment T790M in advanced NSCLC patients treated with EGFR TKIs.

Results: A total of 7 eligible studies containing 179 cases and 281 controls were included in the meta-analysis. The pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were 2.21 (95% CI 1.49-3.29, P<0.001) and 1.24 (95% CI 0.90-1.71, P=0.186), respectively. We also did subgroup analyses on OS and PFS according to patients from various districts.

Methods: Identified literatures from various databases were reviewed. A meta-analysis was performed to evaluate the prognostic role of pretreatment EGFR T790M in advanced EGFR mutant patients treated with EGFR TKIs.

Conclusions: Pretreatment T790M may be a poor prognostic factor for PFS in advanced NSCLC patients treated with EGFR TKIs. However, no significant prognostic effect was found between pretreatment T790M mutation and OS. More studies are needed to demonstrate the prognostic role of pretreatment T790M mutation in advanced NSCLC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16222